Price
Target price
€12.00
€12.00
0.840%
0.1
0.840%
€25.58
01.07.24 / Frankfurt
WKN: A1T7BJ / Symbol: ENTA / Name: Enanta / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Enanta Pharmaceuticals Inc. Stock
Enanta Pharmaceuticals Inc. gained 0.840% compared to yesterday.
Our community is currently high on Enanta Pharmaceuticals Inc. with 6 Buy predictions and 4 Sell predictions.
With a target price of 25 € there is potential for a 108.33% increase which would mean more than doubling the current price of 12.0 € for Enanta Pharmaceuticals Inc..
So far the community has only identified positive things for Enanta Pharmaceuticals Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Enanta Pharmaceuticals Inc. in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
B****
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Enanta Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Enanta Pharmaceuticals Inc. | 0.840% | 7.143% | 7.143% | -38.144% | 36.364% | -67.391% | -83.729% |
| Ardelyx Inc. | -31.220% | -12.398% | -22.159% | 58.645% | -14.913% | -26.597% | - |
| Evolus Inc | 3.550% | 5.155% | -13.559% | 58.140% | 12.707% | -2.857% | - |
| Krystal Biotech | -1.590% | -1.928% | 12.140% | 53.102% | 42.543% | - | - |
Comments
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its price target lowered by analysts at HC Wainwright from $28.00 to $27.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ENTA provided by MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Show more
Ratings data for ENTA provided by MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its price target lowered by analysts at HC Wainwright from $30.00 to $28.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ENTA provided by MarketBeat